BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth, improved profitability, and strategic partnerships like the United contract, which boosts ASPs. The company is expanding its sales force and increasing provider awareness, indicating future growth. Despite some uncertainties in management's responses, the overall outlook is positive with increased guidance and strong market positioning, suggesting a 2% to 8% stock price increase.
Key Financial Performance
Full Year Revenue Growth Achieved 100% year-over-year growth driven by rapid increase in test volume (51% growth) and ASPs (35% growth). Reasons include strong sales team performance, product innovation, and expanded payer contracts.
Adjusted EBITDA Margin Achieved 13% for the full year 2025, reflecting operational efficiency and cost reductions.
Gross Margins Improved by 15 percentage points year-over-year, reaching above 70% in Q4 2025. Reasons include increased ASPs and reduced COGS per test.
GAAP Operating Margin Improved by 36 percentage points year-over-year, driven by automation, AI integration, and operational efficiency.
Q4 Revenue Growth Achieved 113% year-over-year growth, driven by 47% growth in test volume and 47% growth in ASPs.
Prenatal Revenue Increased 98% year-over-year to $86.9 million in Q4 2025, driven by UNITY differentiation and expanded product offerings.
Oncology Revenue Increased 736% year-over-year to $9.1 million in Q4 2025, driven by adoption of Northstar Select and Response, and MolDX coverage.
Overall ASP Increased 35% year-over-year to $495 for 2025, with a Q4 increase to $561. Reasons include payer contracts and higher contribution from oncology tests.
COGS per Test Decreased by 4% year-over-year to $161 in Q4 2025, despite higher oncology test volumes with higher COGS.
Net Income Achieved $4.4 million in Q4 2025 compared to a net loss of $11.5 million in Q4 2024, reflecting improved margins and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
UNITY Fetal Antigen NIPT: Expanded to include Platelet Fetal Antigen NIPT and additional red blood cell antigens, addressing severe prenatal conditions like FNAIT and HDFN.
Northstar Select PGx and CH: Launched add-ons for pharmacogenomics and clonal hematopoiesis, improving therapy selection and liquid biopsy specificity.
UnitedHealthcare contract: Signed in-network contract with the largest U.S. health insurer, reducing friction for patients and physicians, and expected to drive test volume and ASPs.
Medicaid coverage expansion: Added 10 Medicaid states for Carrier PLA code, including Florida, driving ASP increases and further payer contracting.
Revenue growth: Achieved 113% year-over-year revenue growth in Q4 2025, driven by 47% test volume growth and 47% ASP growth.
Cost efficiency: Reduced COGS per test by 4% year-over-year, despite higher oncology test volumes with higher COGS.
MolDX coverage submission: Submitted comprehensive dossier for Northstar Response, aiming for Medicare coverage to significantly boost oncology revenue.
S&P 500 ambition: Long-term goal to enter S&P 500, supported by strong financial performance and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company faces potential challenges in obtaining Medicare coverage for its Northstar Response test, as the MolDX coverage submission is still pending. Approval delays could impact oncology revenue, given that Northstar Response accounts for nearly two-thirds of oncology test volume.
Market access and payer contracts: While the company has made progress in securing payer contracts, including a recent agreement with UnitedHealthcare, being out-of-network with other payers creates friction for patients and physicians, potentially limiting test adoption and lowering ASPs.
Product adoption and integration: The adoption of UNITY as a prenatal screening choice in health systems is contingent on EMR integration, which is expected to take at least six months. Delays in integration could hinder adoption and revenue growth.
Cost structure and product mix: The shift toward a higher proportion of oncology tests, which have higher COGS, could limit near-term margin expansion despite overall gross margin improvements.
Economic uncertainties: The company operates in a highly competitive and rapidly evolving molecular diagnostics market, which could be impacted by broader economic uncertainties affecting healthcare spending and investment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company has raised its 2026 total revenue outlook to a range of $430 million to $445 million, representing growth of 41% to 46% compared to full year 2025.
Product Launches: BillionToOne plans to launch a best-in-class tumor-naive MRD by the end of 2026, which is expected to drive additional growth.
Oncology Revenue: The company expects significant growth in oncology test volumes, driven by the launch of Northstar Select PGx and Northstar Select CH, as well as potential MolDX coverage for Northstar Response.
Prenatal Revenue: The company anticipates continued strong growth in prenatal revenues, supported by the dual launch of expanded Red Blood Cell Fetal Antigen NIPT and Platelet Fetal Antigen NIPT, as well as increased Medicaid coverage.
ASP Growth: Average selling price (ASP) is expected to continue increasing due to additional Medicaid coverage, payer contracts, and broader clinical indications for tests.
Operational Efficiency: The company plans to further reduce cost of goods sold (COGS) per test through AI and automation, while maintaining gross margins near current levels.
Market Access: The company has signed a contract to be in-network with UnitedHealthcare, which is expected to drive both test volume and ASP growth.
Strategic Goals: BillionToOne aims to build a category-defining business, enter the S&P 500, and continue transforming healthcare.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the current awareness level of UNITY among providers who order NIPT, and how does the company plan to increase it?
A:Currently, at least 50% of providers do not know about UNITY. Unaided awareness is around 30%, and aided awareness is around 50%. Among providers who know about UNITY, the company has a 50% market share. The company plans to increase awareness by expanding its sales team, covering the entire U.S., publishing clinical guidelines, and introducing additional products.
Q:What role do MFMs play in driving uptake of UNITY tests?
A:MFMs are key stakeholders, especially for high-risk pregnancies. They influence the tests used by OBs who refer high-risk patients to them. MFMs who advocate for UNITY can encourage OBs to use UNITY for frontline screening, ensuring MFMs have the necessary information to counsel and manage patients.
Q:What was the significance of the increase in active ordering providers in Q4?
A:Q4 saw the highest increase in active ordering providers, indicating strong growth for Q1. The company defines active providers as those who use their products regularly, not just occasionally. This growth is a positive signal for future test volume growth.
Q:What is the company's outlook on gross margins for the year?
A:The company expects gross margins to remain in the high 60% range, possibly reaching the low 70% range. However, they do not anticipate significant expansion in gross margins.
Q:What products are covered under the United contract, and how does it impact ASPs?
A:The United contract covers both prenatal and oncology products. The company expects higher ASPs going forward, as in-network contracts typically result in more reliable reimbursement, even if the agreed percentage of Medicare is lower.
Q:Is the company seeing any impact from competition, such as Natera's Fetal Focus?
A:The company has not observed any impact from competition, as evidenced by record numbers of ordering providers and strong test volume growth in Q4.
Q:What has gone according to plan since the IPO, and what areas need improvement?
A:The company has consistently met or exceeded guidance, with strong operational performance. However, the timing of the IPO and associated activities like conferences and investor meetings have been a distraction from running the business.
Q:What does the guidance assume for prenatal volume growth and market share gains?
A:The guidance is based on the current number of sales team members and their expected growth in territories. It does not include potential upside from large health system opportunities or new product additions.
Q:What drove the $15 million increase in guidance since December?
A:Two-thirds of the increase came from stronger-than-expected test volumes in December, and one-third came from higher-than-expected true-up revenue. The guidance does not include potential upside from the United contract or other developments.
Q:What is the company's strategy for competing in therapy selection and response monitoring?
A:The company focuses on demonstrating the superior sensitivity of its tests, which identify 50% more actionable variants. They engage oncologists through research trials and rely on advocates among physicians to promote their tests. The main bottleneck is getting in front of oncologists, but this is improving as more physicians become advocates.
Q:What is the company's sales force expansion plan for 2026?
A:The company plans to grow its prenatal sales team from 150 to 185 reps and its oncology team from 45 to 65 reps by the end of the year. This growth is designed to maintain high-quality service and manageable turnaround times.
Q:What is the potential size of the health systems opportunity, and when might it impact results?
A:Each health system could represent 10,000 to 30,000 tests per year. While no health system-related growth is included in the 2026 guidance, some systems may start contributing in the second half of the year, setting up strong growth for 2027.
Q:What is the company's approach to managing OpEx and weather-related disruptions in Q1?
A:The company does not anticipate weather-related disruptions in Q1. OpEx is planned to support GAAP profitability, with balanced spending throughout the year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the United contract terms due to confidentiality. They also did not provide a clear average test order per month for Northstar Select customers or detailed assumptions for oncology volume growth split between existing providers and share gains. Additionally, they did not elaborate on the timeline for CMS coverage decisions for response monitoring or the exact impact of health system integrations on 2026 results.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI automation
ASPs test
Antigen NIPT
CH mutation
FNAIT
MFMs
NIPT Platelet
NIPT fetus
Northstar PGx
Northstar Response
Platelet Fetal
Response coverage
Rule
affair
blood cell
cell antigen
combination
committee
contribution oncology
coverage Northstar
debt
depth
evidence
gene
hematopoiesis
incompatibility
increase test
mother antibody
offering biopsy
pace
payer contract
pharmacogenomics
point margin
positive
pregnancy aneuploidy
presentation
productivity
record
risk pregnancy
step
volume ASP
BLLN Transcript
BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript
Positive3-6
The earnings call highlights strong revenue growth, improved profitability, and strategic partnerships like the United contract, which boosts ASPs. The company is expanding its sales force and increasing provider awareness, indicating future growth. Despite some uncertainties in management's responses, the overall outlook is positive with increased guidance and strong market positioning, suggesting a 2% to 8% stock price increase.
BillionToOne, Inc. (BLLN) Q3 2025 Earnings Call Transcript
Positive12-12
The earnings call highlights strong financial performance with significant revenue growth, improved gross margins, and a shift from net loss to net income. The Q&A section addresses strategic investments and a conservative guidance approach. Although management avoided specific 2026 guidance, the overall outlook is optimistic with robust revenue growth and strategic expansion plans in prenatal and oncology sectors. These factors suggest a positive stock price movement over the next two weeks.
BLLN Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
